Lab Sciences
Top stories summarized by our editors
5/18/2017

Keytruda, or pembrolizumab, has received accelerated approval from the FDA as a treatment for children and adults with refractory classical Hodgkin lymphoma or those who have experienced relapses after at least three previous therapies. An added warning and precaution highlights the risk of complications for patients who received allogenic hematopoietic stem cell transplants after taking pembrolizumab.

5/18/2017

A mouse study of a method for transplanting cells into a liver using irreversible electroporation found it was associated with increased stem cell survival and potential restoration of the failing organ. Researchers from the University of California at San Francisco used electrical pulses to kill cells in a section of the diseased organ, creating room for the implanted cells while maintaining the extracellular matrix, according to the study in the journal Bio Techniques.

5/17/2017

Ian Hurll was a toddler when his 6-year-old sister died of leukemia. Hurll, now 22, donated bone marrow from his hip to a stranger who had the same cancer as his sister.

More Summaries:
bone marrow, leukemia
5/17/2017

Tanzania is beginning a public health mission to raise awareness about Ebola virus risks and safety along the nation's border with the Democratic Republic of Congo.

Full Story:
Daily News (Tanzania)
5/17/2017

Researchers with the Johns Hopkins Bloomberg School of Public Health said the Zika virus would have an economic impact of $1.2 billion with a 1% attack rate along the US Gulf Coast. The costs would include medical and Medicaid expenditures, clinical outcomes and productivity losses, according to the study in the journal PLOS Neglected Tropical Diseases.

5/17/2017

Immunomic Therapeutics gained a license for cytomegalovirus immunotherapy technology from Annias Immunotherapeutics, and it will be developed in combination with Immunomic's LAMP-Vax technology as a potential therapy for cancers expressing CMV.

5/16/2017

The FDA has granted Imara's experimental drug candidate IMR-687 a rare pediatric disease designation, the first time the designation has been given to a sickle cell disease treatment. The drug is being assessed in an early-stage trial for safety and pharmacokinetics in healthy volunteers, with a Phase IIa study planned in adults with the disease pending a positive outcome of the Phase Ia study.

Full Story:
Rare Disease Report
More Summaries:
Imara
5/16/2017

The i-STAT Glucose test from Abbott Laboratories has been granted 510(k) clearance for use on the i-STAT Alinity System. The test with the Alinity platform is designed for quantitative measurement of glucose in venous and arterial whole blood in point-of-care or clinical laboratory settings.

More Summaries:
Abbott Laboratories, Abbott, FDA
5/16/2017

A new biofluid assay developed by scientists from Beaumont Hospital in Royal Oak, Mich., is capable of detecting the presence of Zika in urine within 30 minutes. The test, which is in the early stage of development, uses color change as an indication of Zika infection.

More Summaries:
Beaumont Hospital, Zika
5/16/2017

Point-of-care HbA1c "is superior for identifying unknown chronic hyperglycemia, particularly prediabetes" versus standard diabetes screening tests, a study found. POCT HbA1c was compared with standard testing, and it identified significantly more patients with undiagnosed diabetes or prediabetes, 10% and 53%, respectively, versus 8% and 33%.

More Summaries:
diabetes, hyperglycemia